Medisca and EUROAPI Form Strategic Partnership to Expand API Access for Pharmaceutical Compounding
Medisca and EUROAPI have entered into a strategic partnership designed to expand access to active pharmaceutical ingredients (APIs) for the pharmaceutical compounding market, with an initial focus on North America and plans to support broader international growth. The collaboration combines Medisca’s longstanding expertise in pharmaceutical compounding and personalized medicine with EUROAPI’s European manufacturing capabilities, technical expertise and focus on quality, green chemistry and sustainability.
The partnership is expected to create differentiated access to selected APIs for compounders while establishing a broader platform for future commercial opportunities, additional markets and collaboration in peptides. Under the agreement, Medisca will become EUROAPI’s first strategic distribution partner specifically focused on bringing EUROAPI-manufactured APIs to the North American pharmaceutical compounding market.
The companies will initially work through exclusive supply arrangements for selected APIs, with the potential to expand the portfolio over time. The partnership is also intended to support customer-focused initiatives, technical and educational activities and further opportunities to connect pharmaceutical manufacturing capabilities with the changing requirements of compounders and personalized medicine providers.
For Medisca, the agreement represents another step in its strategy of strengthening access to pharmaceutical ingredients through direct relationships with manufacturers. Rather than focusing solely on expanding the number of products available to customers, the company is taking a broader approach that encompasses sourcing, manufacturing quality, technical documentation, regulatory information and customer support.
For more than 30 years, Medisca has developed its business around the evolving needs of pharmaceutical compounders. Its approach extends beyond product distribution to include relationships with manufacturers, technical information, product specifications, documentation, quality systems and services that help support the compounding process from the source of an ingredient through to the customer.
The new relationship with EUROAPI builds on that model by connecting European API manufacturing expertise with Medisca’s established presence and understanding of the North American compounding market.
“This partnership marks an important milestone in the growth of Medisca,” said Peng Li, Chief Business Officer at Medisca. “EUROAPI brings deep manufacturing and technical expertise, with a strong focus on quality, green chemistry and sustainability. These strengths align with the evolving needs of the compounding market as personalized medicine continues to grow across telehealth, wellness and new areas of patient care. Together, we are expanding API access, building new opportunities across markets and advancing collaboration in peptides. We are proud to partner with EUROAPI and confident in the long-term potential of what we can build together.”
Expanding API Access for Pharmaceutical Compounding
Access to reliable APIs is an important component of pharmaceutical compounding, where medications can be prepared or customized to address individual patient requirements. Compounders depend not only on the availability of active ingredients but also on consistent quality, appropriate specifications, technical information and documentation that can support their operations.
The Medisca-EUROAPI partnership is intended to address these needs by creating a stronger connection between API manufacturing and the specialized requirements of the compounding sector.
Through the collaboration, EUROAPI will make available relevant technical and regulatory information associated with the APIs supplied through the partnership. Medisca will complement this manufacturing and technical foundation with its own quality infrastructure, customer relationships and knowledge of the compounding market.
This approach is designed to provide customers with more than a larger product catalog. By combining manufacturing capabilities with market insight and technical support, the companies aim to create a supply model that can evolve in response to changing requirements across pharmaceutical compounding and personalized medicine.
The arrangement also provides a platform for introducing additional APIs as the partnership develops. Medisca and EUROAPI expect to evaluate new products and opportunities based on customer needs, market developments and the companies’ respective capabilities.
Focus on Quality, Technical Expertise and Sustainability
Quality is a central component of the strategic relationship. For pharmaceutical compounders, confidence in the source and quality of APIs is an important consideration when selecting materials for use within compounding operations.
Medisca’s model emphasizes the importance of understanding an ingredient from its manufacturing source through its distribution and use. This includes consideration of manufacturer capabilities, product specifications, technical documentation and quality controls.
EUROAPI brings extensive experience in API development and manufacturing, together with a focus on technical expertise and manufacturing standards. Its emphasis on green chemistry and sustainability also aligns with Medisca’s broader interest in responsible sourcing and environmental considerations within its supply chain.
The companies believe that combining these capabilities can strengthen the overall value proposition for customers. EUROAPI contributes manufacturing and technical knowledge, while Medisca brings its understanding of compounders and its established infrastructure for serving the pharmaceutical compounding market.
The partnership therefore represents a connection between two complementary parts of the pharmaceutical supply chain: specialized API manufacturing and customer-focused distribution and support.
Building a Broader International Platform
Although North America is the initial focus of the relationship, the companies intend for the partnership to extend beyond the initial market.
The agreement creates a framework through which Medisca and EUROAPI can evaluate opportunities in additional geographic markets and potentially expand their respective commercial reach. As customer requirements and personalized medicine markets continue to develop internationally, the companies expect the partnership to provide opportunities for additional collaboration.
Medisca’s global operations and experience across personalized medicine and pharmaceutical supply chain solutions provide a foundation for international expansion. EUROAPI’s European manufacturing footprint and technical capabilities add another dimension to the collaboration.
The companies also plan to work together on customer initiatives, training and commercial activities. These efforts could help customers better understand the available APIs, their technical characteristics and the broader capabilities supporting their supply.
By developing the relationship beyond a conventional distribution arrangement, Medisca and EUROAPI are positioning the partnership as a longer-term collaboration focused on market development and innovation.
Advancing Collaboration in Peptides
Peptides represent another important area of potential growth under the partnership.
As pharmaceutical research and personalized medicine continue to advance, peptides have become an increasingly important area of interest across multiple therapeutic and healthcare applications. Their complex structures and manufacturing requirements can create specialized challenges, making technical expertise and reliable manufacturing capabilities important components of the supply chain.
Medisca is continuing to develop its global peptide strategy in support of pharmaceutical compounding and personalized medicine. Through its relationship with EUROAPI, the company intends to explore opportunities that combine its understanding of the compounding market with EUROAPI’s capabilities in complex API development and manufacturing.
The companies view this collaboration as a foundation for future work in peptides rather than a standalone initiative. As the market evolves, Medisca and EUROAPI expect to assess opportunities where their complementary capabilities can support new products, customer requirements and commercial initiatives.
“Medisca’s depth of expertise in pharmaceutical compounding and its close understanding of the market make it a strong strategic partner for EUROAPI,” said Frederic Robert, Chief Commercial Officer at EUROAPI. “This relationship creates new opportunities to broaden access to our APIs, expand our reach in the compounding market and develop our collaboration in areas such as peptides. We see significant potential to grow together over the long term.”
Supporting the Growth of Personalized Medicine
The partnership comes as personalized medicine continues to influence how healthcare providers and patients approach treatment. Customized medications can play a role when commercially available products do not adequately address a particular patient requirement, creating demand for specialized compounding capabilities and the ingredients needed to support them.
Medisca has built its business around this evolving healthcare environment. The company provides products, formulas, expertise, education and analytical testing services intended to support pharmaceutical compounding and personalized wellness.
Its portfolio includes more than 2,000 products, supported by a library of more than 10,000 proprietary and customized medication formulas. The company also provides continuing healthcare education and analytical testing services.
By expanding its relationships with API manufacturers such as EUROAPI, Medisca aims to reinforce the supply chain supporting these activities while improving access to differentiated ingredients.
The partnership also reflects the changing nature of the pharmaceutical supply chain. Manufacturers and distributors increasingly need to work closely together to address requirements related to quality, technical information, sustainability, market access and customer demand. Strategic relationships can help connect these capabilities more effectively than conventional transactional supply arrangements.
For both companies, the agreement is positioned as the beginning of a longer-term relationship rather than a single product launch.
Medisca and EUROAPI intend to continue evaluating opportunities to introduce additional APIs, expand into other markets and strengthen collaboration in areas such as peptides. Customer initiatives, training programs and commercial activities are also expected to contribute to the development of the partnership.
For Medisca, the relationship supports its broader objective of creating differentiated API access for pharmaceutical compounders while strengthening the company’s connections with pharmaceutical manufacturers.
For EUROAPI, the partnership provides an opportunity to expand the reach of its European-manufactured APIs into the North American compounding market through a specialized distribution partner with established industry expertise.
Together, the companies aim to build a supply and collaboration model that combines manufacturing expertise, technical rigor, quality infrastructure and direct knowledge of customer needs.
The partnership ultimately reflects a shared focus on supporting the evolving pharmaceutical compounding landscape. As personalized medicine, telehealth, wellness services and other areas of patient-centered care continue to develop, demand for flexible and reliable pharmaceutical ingredients is expected to evolve as well.
By combining Medisca’s compounding expertise and market knowledge with EUROAPI’s API manufacturing capabilities, the companies are establishing a foundation for expanded product access, international growth and future innovation.
Customers interested in EUROAPI-manufactured APIs available through Medisca can explore the companies’ offerings through Medisca.
Founded in 1989, Medisca is a provider of personalized medicine and pharmaceutical supply chain solutions. The company offers a portfolio of more than 2,000 products, along with more than 10,000 proprietary and customized medication formulas.
Medisca supports pharmaceutical compounding through products, expertise and services that include continuing healthcare education and analytical testing. The company serves diverse wellness sectors across multiple international markets and focuses on developing solutions designed to address evolving healthcare and personalized medicine needs.
Through its product portfolio, technical capabilities and relationships across the pharmaceutical supply chain, Medisca works to connect manufacturers, compounders and healthcare professionals while supporting the development of personalized wellness solutions.
About EUROAPI
EUROAPI is focused on reinventing active pharmaceutical ingredients to sustainably meet customers’ and patients’ needs around the world. We are a leading player with approximately 200 products in our portfolio, offering a large span of technologies while also developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO) activities.
With strong R&D capabilities and five manufacturing sites located in Europe, EUROAPI provides its clients with high-quality API solutions in more than 80 countries. Our 3000+ people are committed to building together the future of public health by advancing and securing access to essential active ingredients, at the core of the healthcare value chain. EUROAPI is listed on Euronext Paris: EAPI. Find out more at www.euroapi.com and follow us on LinkedIn.